{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T11:09:37Z","timestamp":1773140977119,"version":"3.50.1"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,27]],"date-time":"2022-12-27T00:00:00Z","timestamp":1672099200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism Reports"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.ymgmr.2022.100952","type":"journal-article","created":{"date-parts":[[2023,1,2]],"date-time":"2023-01-02T12:18:57Z","timestamp":1672661937000},"page":"100952","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Distinctive accumulation of globotriaosylceramide and globotriaosylsphingosine in a mouse model of classic Fabry disease"],"prefix":"10.1016","volume":"34","author":[{"given":"Atsumi","family":"Taguchi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariko","family":"Mikame","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroki","family":"Maruyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgmr.2022.100952_bb0005","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1056\/NEJM196705252762101","article-title":"Enzymatic defect in Fabry's disease Ceramidetrihexosidase deficiency","volume":"276","author":"Brady","year":"1967","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymgmr.2022.100952_bb0010","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1136\/jmedgenet-2019-106467","article-title":"Use of a rare disease registry for establishing phenotypic classification of previously unassigned GLA variants: a consensus classification system by a multispecialty Fabry disease genotype-phenotype workgroup","volume":"57","author":"Germain","year":"2020","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.ymgmr.2022.100952_bb0015","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJM200107053450102","article-title":"International collaborative Fabry disease study, safety and efficacy of recombinant human alpha-galactosidase a replacement therapy in Fabry\u2019s disease","volume":"345","author":"Eng","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymgmr.2022.100952_bb0020","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1001\/jama.285.21.2743","article-title":"Enzyme replacement therapy in Fabry disease: a randomized controlled trial","volume":"285","author":"Schiffmann","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.ymgmr.2022.100952_bb0025","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1007\/s40265-016-0607-y","article-title":"Migalastat: first global approval","volume":"76","author":"Markham","year":"2016","journal-title":"Drugs"},{"key":"10.1016\/j.ymgmr.2022.100952_bb0030","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.ymgme.2011.12.006","article-title":"Anti-alpha-galactosidase a antibody response to agalsidase beta treatment: data from the Fabry registry","volume":"105","author":"Wilcox","year":"2012","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgmr.2022.100952_bb0035","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/gim.2016.122","article-title":"The validation of pharmacogenetics for the identification of Fabry patients to be treated with migalastat","volume":"19","author":"Benjamin","year":"2017","journal-title":"Genet Med"},{"key":"10.1016\/j.ymgmr.2022.100952_bb0040","doi-asserted-by":"crossref","first-page":"956","DOI":"10.3390\/ijms21030956","article-title":"Assessment of gene variant amenability for pharmacological chaperone therapy with 1-deoxygalactonojirimycin in Fabry disease","volume":"21","author":"Lukas","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymgmr.2022.100952_bb0045","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1086\/422366","article-title":"Long-term safety and efficacy of enzyme replacement therapy for Fabry disease","volume":"75","author":"Wilcox","year":"2004","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.ymgmr.2022.100952_bb0050","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1073\/pnas.0712309105","article-title":"Elevated globotriaosylsphingosine is a hallmark of Fabry disease","volume":"105","author":"Aerts","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ymgmr.2022.100952_bb0055","first-page":"70","article-title":"Reduction of elevated plasma globotriaosylsphingosine in patients with classic Fabry disease following enzyme replacement therapy","volume":"2011","author":"van Breemen","year":"1812","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ymgmr.2022.100952_bb0060","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1136\/jmedgenet-2014-102872","article-title":"Plasma globotriaosylsphingosine in relation to phenotypes of Fabry disease","volume":"52","author":"Smid","year":"2015","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.ymgmr.2022.100952_bb0065","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/s41436-020-00968-z","article-title":"Assessment of plasma lyso-Gb3 for clinical monitoring of treatment response in migalastat-treated patients with Fabry disease","volume":"23","author":"Bichet","year":"2021","journal-title":"Genet Med"},{"key":"10.1016\/j.ymgmr.2022.100952_bb0070","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1021\/ac203433e","article-title":"Urinary globotriaosylsphingosine-related biomarkers for Fabry disease targeted by metabolomics","volume":"84","author":"Auray-Blais","year":"2012","journal-title":"Anal. Chem."},{"key":"10.1016\/j.ymgmr.2022.100952_bb0075","doi-asserted-by":"crossref","first-page":"9039","DOI":"10.1021\/ac401542k","article-title":"A metabolomic study to identify new globotriaosylceramide-related biomarkers in the plasma of Fabry disease patients","volume":"85","author":"Manwaring","year":"2013","journal-title":"Anal. Chem."},{"key":"10.1016\/j.ymgmr.2022.100952_bb0080","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0144958","article-title":"Distributions of globotriaosylceramide isoforms, and globotriaosylsphingosine and its analogues in an alpha-galactosidase a knockout mouse, a model of Fabry disease","volume":"10","author":"Sueoka","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.ymgmr.2022.100952_bb0085","doi-asserted-by":"crossref","first-page":"5577","DOI":"10.1074\/jbc.RA120.012665","article-title":"Determination of globotriaosylceramide analogs in the organs of a mouse model of Fabry disease","volume":"295","author":"Ishii","year":"2020","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ymgmr.2022.100952_bb0090","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1042\/BJ20130825","article-title":"A symptomatic Fabry disease mouse model generated by inducing globotriaosylceramide synthesis","volume":"456","author":"Taguchi","year":"2013","journal-title":"Biochem. J."},{"key":"10.1016\/j.ymgmr.2022.100952_bb0095","doi-asserted-by":"crossref","first-page":"4544","DOI":"10.1096\/fj.201701374R","article-title":"Medullary thick ascending limb impairment in the GlatmTg(CAG-A4GALT) Fabry model mice","volume":"32","author":"Maruyama","year":"2018","journal-title":"FASEB J."},{"key":"10.1016\/j.ymgmr.2022.100952_bb0100","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1096\/fba.2019-00080","article-title":"Low bone mineral density due to secondary hyperparathyroidism in the GlatmTg(CAG-A4GALT) mouse model of Fabry disease","volume":"2","author":"Maruyama","year":"2020","journal-title":"FASEB Bioadv"},{"key":"10.1016\/j.ymgmr.2022.100952_bb0105","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.ymgme.2018.02.014","article-title":"Fabry disease revisited: management and treatment recommendations for adult patients","volume":"123","author":"Ortiz","year":"2018","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgmr.2022.100952_bb0110","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1086\/318809","article-title":"A phase 1\/2 clinical trial of enzyme replacement in Fabry disease: pharmacokinetic, substrate clearance, and safety studies","volume":"68","author":"Eng","year":"2001","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.ymgmr.2022.100952_bb0115","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/gim.2018.31","article-title":"Effectiveness of plasma lyso-Gb3 as a biomarker for selecting high-risk patients with Fabry disease from multispecialty clinics for genetic analysis","volume":"21","author":"Maruyama","year":"2019","journal-title":"Genet Med"},{"key":"10.1016\/j.ymgmr.2022.100952_bb0120","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1002\/1873-3468.12104","article-title":"Lysosomal glycosphingolipid catabolism by acid ceramidase: formation of glycosphingoid bases during deficiency of glycosidases","volume":"590","author":"Ferraz","year":"2016","journal-title":"FEBS Lett."},{"key":"10.1016\/j.ymgmr.2022.100952_bb0125","doi-asserted-by":"crossref","first-page":"389","DOI":"10.3390\/cimb43010032","article-title":"Plasma globotriaosylsphingosine and \u03b1-galactosidase a activity as a combined screening biomarker for Fabry disease in a large Japanese cohort","volume":"43","author":"Maruyama","year":"2021","journal-title":"Curr Issues Mol Biol"},{"key":"10.1016\/j.ymgmr.2022.100952_bb0130","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1253\/circj.CJ-19-0110","article-title":"Plasma globotriaosylsphingosine level as a primary screening target for Fabry disease in patients with left ventricular hypertrophy","volume":"83","author":"Yamashita","year":"2019","journal-title":"Circ. J."},{"key":"10.1016\/j.ymgmr.2022.100952_bb0135","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ymgme.2017.05.001","article-title":"Favourable effect of early versus late start of enzyme replacement therapy on plasma globotriaosylsphingosine levels in men with classical Fabry disease","volume":"121","author":"Arends","year":"2017","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgmr.2022.100952_bb0140","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0057631","article-title":"Migalastat HCl reduces globotriaosylsphingosine (lyso-Gb3) in Fabry transgenic mice and in the plasma of Fabry patients","volume":"8","author":"Young-Gqamana","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ymgmr.2022.100952_bb0145","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1038\/gim.2013.53","article-title":"Analysis of left ventricular mass in untreated men and in men treated with agalsidase-beta: data from the Fabry registry","volume":"15","author":"Germain","year":"2013","journal-title":"Genet Med"}],"container-title":["Molecular Genetics and Metabolism Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214426922001124?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214426922001124?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T12:52:35Z","timestamp":1762001555000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2214426922001124"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":29,"alternative-id":["S2214426922001124"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgmr.2022.100952","relation":{},"ISSN":["2214-4269"],"issn-type":[{"value":"2214-4269","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Distinctive accumulation of globotriaosylceramide and globotriaosylsphingosine in a mouse model of classic Fabry disease","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgmr.2022.100952","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100952"}}